269 related articles for article (PubMed ID: 23880303)
41. [Developing FGFR inhibitors as potential anti-cancer agents].
Zsákai L; Németh G; Szántai-Kis C; Greff Z; Horváth Z; Szokol B; Baska F; Boon TC; Orfi L; Kéri G
Acta Pharm Hung; 2013; 83(2):47-56. PubMed ID: 23926649
[TBL] [Abstract][Full Text] [Related]
42. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE.
Tannheimer SL; Rehemtulla A; Ethier SP
Breast Cancer Res; 2000; 2(4):311-20. PubMed ID: 11056689
[TBL] [Abstract][Full Text] [Related]
43. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations.
Wilkie AO
Cytokine Growth Factor Rev; 2005 Apr; 16(2):187-203. PubMed ID: 15863034
[TBL] [Abstract][Full Text] [Related]
44. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.
Parish A; Schwaederle M; Daniels G; Piccioni D; Fanta P; Schwab R; Shimabukuro K; Parker BA; Helsten T; Kurzrock R
Cell Cycle; 2015; 14(13):2121-8. PubMed ID: 25950492
[TBL] [Abstract][Full Text] [Related]
45. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
[TBL] [Abstract][Full Text] [Related]
46. FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells.
Sturla LM; Merrick AE; Burchill SA
Br J Cancer; 2003 Oct; 89(7):1276-84. PubMed ID: 14520460
[TBL] [Abstract][Full Text] [Related]
47. Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis.
Mikhaylenko DS; Alekseev BY; Zaletaev DV; Goncharova RI; Nemtsova MV
Biochemistry (Mosc); 2018 Aug; 83(8):930-943. PubMed ID: 30208830
[TBL] [Abstract][Full Text] [Related]
48. A competitive PCR-based method to measure human fibroblast growth factor receptor 1-4 (FGFR1-4) gene expression.
Tartaglia M; Fragale A; Battaglia PA
DNA Cell Biol; 2001 Jun; 20(6):367-79. PubMed ID: 11445008
[TBL] [Abstract][Full Text] [Related]
49. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations.
Ho HK; Yeo AH; Kang TS; Chua BT
Drug Discov Today; 2014 Jan; 19(1):51-62. PubMed ID: 23932951
[TBL] [Abstract][Full Text] [Related]
50. Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.
Gallo LH; Nelson KN; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2015 Aug; 26(4):425-49. PubMed ID: 26003532
[TBL] [Abstract][Full Text] [Related]
51. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
[TBL] [Abstract][Full Text] [Related]
52. FGF-mediated aspects of skeletal muscle growth and differentiation are controlled by a high affinity receptor, FGFR1.
Templeton TJ; Hauschka SD
Dev Biol; 1992 Nov; 154(1):169-81. PubMed ID: 1426624
[TBL] [Abstract][Full Text] [Related]
53. Recent developments and advances of FGFR as a potential target in cancer.
Xue WJ; Li MT; Chen L; Sun LP; Li YY
Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
[TBL] [Abstract][Full Text] [Related]
54. Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.
Giacomini A; Chiodelli P; Matarazzo S; Rusnati M; Presta M; Ronca R
Pharmacol Res; 2016 May; 107():172-185. PubMed ID: 27013279
[TBL] [Abstract][Full Text] [Related]
55. Recent advances of dual FGFR inhibitors as a novel therapy for cancer.
Liang Q; Wang J; Zhao L; Hou J; Hu Y; Shi J
Eur J Med Chem; 2021 Mar; 214():113205. PubMed ID: 33556787
[TBL] [Abstract][Full Text] [Related]
56. FGFR-TKI resistance in cancer: current status and perspectives.
Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
[TBL] [Abstract][Full Text] [Related]
57. Targeting fibroblast growth factor receptor pathway in breast cancer.
Criscitiello C; Esposito A; De Placido S; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764
[TBL] [Abstract][Full Text] [Related]
58. Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy.
Saichaemchan S; Ariyawutyakorn W; Varella-Garcia M
Curr Mol Med; 2016; 16(1):40-62. PubMed ID: 26695695
[TBL] [Abstract][Full Text] [Related]
59. Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.
Szlachcic A; Zakrzewska M; Lobocki M; Jakimowicz P; Otlewski J
Drug Des Devel Ther; 2016; 10():2547-60. PubMed ID: 27563235
[TBL] [Abstract][Full Text] [Related]
60. [Development and ligand-protein interaction of small molecule anti-tumor FGFR inhibitors].
Li XL; Qiu R; Li J; Hai L; Wu Y
Yao Xue Xue Bao; 2016 Nov; 51(11):1689-97. PubMed ID: 29908111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
